VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-101 in Solid Tumors
SAN DIEGO — Oct. 19, 2020 — VelosBio Inc. (VelosBio), a clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), today announced that the first patient has been dosed in a Phase 2 trial of VLS-101 in patients with solid tumors. VLS-101, the company’s lead product candidate, is an antibody-drug conjugate (ADC) that targets ROR1.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.